COMMUNIQUÉS West-GlobeNewswire

HealthTab™ and HeartEye Open New Referral Pathway into Community Pharmacy
08/10/2026
VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) is pleased to announce that its wholly owned subsidiary, HealthTab Ltd. (“HealthTab”), has [...]
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
08/10/2026
CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Tilray Brands Delivers Record Q1 Fiscal 2027 Revenue and Record Q1 Gross Profit, Demonstrating the Power of Its Global Platform, Driven by Double-Digit Year-Over-Year Growth Across International Cannabis, Beverage and Pharmaceutical Distribution
08/10/2026
First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum Record First-Quarter Net Revenue [...]
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
08/10/2026
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
08/10/2026
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
08/10/2026
Leadership investment supports expanded hospital commercial push POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative [...]
Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program
08/10/2026
Management call today at 3.30 pm CEST Newron received the anticipated FDA written communication on clinical hold at U.S. study centers and is reviewing feedback and preparing its response ENIGMA-TRS 1 enrollment [...]
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
08/10/2026
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability [...]
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
08/10/2026
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
What Actually Keeps Weight Off After a Weight Loss Program
08/10/2026
Baltimore, MD, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Weight regain after initial weight loss is a recognized pattern among individuals pursuing lasting metabolic change. Trilivy™, a science-backed, coach-guided metabolic [...]
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
08/10/2026
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases Overall [...]
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
08/10/2026
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will [...]
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
08/10/2026
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial [...]
NextWave Peptides Builds a Clearer Standard for Research Peptide Information, Documentation, and Fulfillment
08/10/2026
New York, USA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- U.S. Based Research Peptide Company Focuses on Transparent Product Information, Reviewable Documentation, Competitive Pricing, and Direct Customer Support NextWave [...]
Bio Usawa Takes Major Step Toward Building a Self-Sustaining Biotechnology Ecosystem in Africa
08/10/2026
The establishment of Botswana subsidiary strengthens regional capacity and expands access to affordable biologics SAN FRANCISCO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology today announced the launch of [...]
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
08/10/2026
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx [...]
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
08/10/2026
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod [...]
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
08/10/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Regulated information – inside information: Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range
08/10/2026
Regulated information – inside information Nazareth-De Pinte (Belgium)/Rotterdam (The Netherlands), 8 October 2026 – 7:00 AM CET Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and [...]

Pages